BIOMAT Database Logo BIOMAT Database Logo

Long-term survivors of primary central nervous system lymphoma. 2017

Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.

In this study, we provide long-term outcome data of patients with primary central nervous system lymphoma. The long-term outcomes of PCNSL patients diagnosed between 1982 and 2006 were reviewed. Neurological late neurotoxicity symptoms, neuroradiological brain atrophy and leukoencephalopathy were evaluated. Surviving patients completed the Quality of Life Questionnaire-30 and Brain Cancer Module-20. The differences in overall survival were assessed using the Kaplan-Meier method and log-rank test. The differences between groups in terms of each investigated parameter were analyzed using the Wilcoxon signed-rank test. Among 112 PCNSL patients, there were 33 (29.4%) long-term (> 5 years) survivors. The median survival of all long-term survivors was 105.7 months; of these, 8 (7.1%) were alive at the latest follow-up, with a mean survival time of 170.2 months (range, 121.8–286.4). Clinical assessment revealed severe neurotoxicity in 14 patients (42.4%), moderate neurotoxicity in 5 (15.1%), and normal status in 14 (42.4%). Correlations were seen between the neuroradiological imaging score changes and neurocognitive condition (P=0.0001), neurocognitive condition and the whole brain irradiation dose (P=0.0004), and atrophy and the whole brain irradiation dose (P=0.0035). A more severe clinical condition was found to be associated with increasing age and whole brain irradiation dose in long-term survivors with PCNSL.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016543 Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. CNS Neoplasm,CNS Neoplasms,Central Nervous System Neoplasm,Central Nervous System Tumor,Neoplasms, Central Nervous System,Primary Central Nervous System Neoplasm,Central Nervous System Neoplasms, Primary,Central Nervous System Tumors,Primary Central Nervous System Neoplasms,Tumors, Central Nervous System,Neoplasm, CNS,Neoplasms, CNS
D017741 Survivors Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events. Long-Term Survivors,Long Term Survivors,Long-Term Survivor,Survivor,Survivor, Long-Term,Survivors, Long-Term

Related Publications

Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Primary malignant lymphoma of the central nervous system--report of four long-term survivors.
September 1995, Neurologia medico-chirurgica,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Retinopathy in survivors of primary central nervous system lymphoma.
December 2006, Neurology,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Long-term survival in AIDS-related primary central nervous system lymphoma.
January 2017, Neuro-oncology,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Cognitive functions in survivors of primary central nervous system lymphoma.
February 2004, Neurology,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.
August 1994, Journal of neurosurgery,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
April 2008, Cancer,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
May 2003, Journal of neuro-oncology,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Primary central nervous system lymphoma.
January 2015, International ophthalmology clinics,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Primary central nervous system lymphoma.
January 2018, Therapeutic advances in neurological disorders,
Ryuya Yamanaka, and Ken Morii, and Masakazu Sano, and Jumpei Homma, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
Primary central nervous system lymphoma.
April 1985, Journal of neurosurgery,
Copied contents to your clipboard!